Hagen W, Födinger M, Heinz G, Buchmayer H, Hörl W H, Sunder-Plassmann G
Division of Nephrology and Dialysis, Department of Medicine III, University of Vienna, Vienna, Austria.
Kidney Int Suppl. 2001 Feb;78:S253-7. doi: 10.1046/j.1523-1755.2001.59780253.x.
The total homocysteine (tHcy) plasma level, which is partly determined by the MTHFR 677C-->T genotype, may be associated with vascular disease. We prospectively examined the influence of MTHFR genotypes (677C-->T, 1298A-->C) and tHcy plasma concentration on all cause mortality and graft outcomes of renal transplant recipients.
Baseline tHcy plasma levels of 189 patients (three groups with either the MTHFR 677CC, CT or TT genotype, including 63 patients in each group, were matched for age, gender, body mass index and creatinine clearance at baseline), were obtained between September 1996 and May 1997. Follow-up data (time until return to dialysis therapy, time and cause of death) were collected from April to June 1999. Kaplan-Meier survival estimations were calculated and plotted, the groups (three MTHFR 677C-->T genotype groups, or three MTHFR 1298A-->C genotype groups, or two groups with tHcy plasma levels above/below 15 micromol/L) were compared by log-rank test. Age, gender, body mass index (BMI), time since transplantation, serum creatinine, creatinine clearance, combined MTHFR 677C-->T/1298A-->C genotypes, tHcy, folate and vitamin B12 plasma levels were evaluated with regard to graft and patient survival in a multivariate Cox-proportional hazard regression model.
During the follow-up period of 2.26 +/- 0.66 years, 9 patients died (5 in the TT, 2 in the CT and 2 in the CC genotype group; P = 0.34) and 22 returned to dialysis treatment (7 in the TT, 9 in the CT and 6 in the CC genotype group; P = 0.65). There was also no influence of MTHFR 1298A-->C genotypes (AA genotype, 114 patients; AC genotype, 64 patients; CC genotype, 11 patients) on patient or graft survival (P = 0.7087 and P = 0.1633, respectively). Two of 93 patients with a tHcy plasma level < or = 15 micromol/L died, in contrast to 7 of 96 patients in the tHcy > 15 micromol/L group, P = 0.0778. Two patients in the low tHcy group had to return to dialysis, in contrast to 20 patients in the high tHcy group (P = 0.0001). In the multivariate model there was no significant predictor of patient survival, and the serum creatinine was the only predictor of graft survival (P < 0.0001).
In summary, our study shows that neither MTHFR 677C-->T/1298A-->C genotypes nor hyperhomocysteinemia are independently associated with patient or graft survival following kidney transplantation.
血浆总同型半胱氨酸(tHcy)水平部分由亚甲基四氢叶酸还原酶(MTHFR)677C→T基因型决定,可能与血管疾病相关。我们前瞻性地研究了MTHFR基因型(677C→T、1298A→C)和血浆tHcy浓度对肾移植受者全因死亡率和移植肾结局的影响。
1996年9月至1997年5月期间,获取了189例患者的基线血浆tHcy水平(分为MTHFR 677CC、CT或TT基因型三组,每组63例,在年龄、性别、体重指数和基线肌酐清除率方面进行匹配)。1999年4月至6月收集随访数据(直至恢复透析治疗的时间、死亡时间和原因)。计算并绘制Kaplan-Meier生存估计曲线,通过对数秩检验比较各组(三个MTHFR 677C→T基因型组、三个MTHFR 1298A→C基因型组或血浆tHcy水平高于/低于15 μmol/L的两组)。在多变量Cox比例风险回归模型中,评估年龄、性别、体重指数(BMI)、移植后时间、血清肌酐、肌酐清除率、联合MTHFR 677C→T/1298A→C基因型、tHcy、叶酸和维生素B12血浆水平对移植肾和患者生存的影响。
在2.26±0.66年的随访期内,9例患者死亡(TT基因型组5例,CT基因型组2例,CC基因型组2例;P = 0.34),22例恢复透析治疗(TT基因型组7例,CT基因型组9例,CC基因型组6例;P = 0.65)。MTHFR 1298A→C基因型(AA基因型114例、AC基因型64例、CC基因型11例)对患者或移植肾生存也无影响(分别为P = 0.7087和P = 0.1633)。血浆tHcy水平≤15 μmol/L的93例患者中有2例死亡,而tHcy>15 μmol/L组的96例患者中有7例死亡,P = 0.0778。低tHcy组有2例患者不得不恢复透析,而高tHcy组有20例患者(P = 0.0001)。在多变量模型中,没有患者生存的显著预测因素,血清肌酐是移植肾生存的唯一预测因素(P < 0.0001)。
总之,我们的研究表明,MTHFR 677C→T/1298A→C基因型和高同型半胱氨酸血症均与肾移植后患者或移植肾生存无独立相关性。